The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism
Abstract Background Heart failure (HF) is one of the most common causes of cardiovascular diseases in the world. Currently, the drugs used to treat HF in the clinic may cause serious side effects. Liguzinediol, 2, 5-dimethyl-3, 6-dimethyl-pyrazine, is a compound synthesized after the structural modi...
Main Authors: | Qi Chen, Dini Zhang, Yunhui Bi, Weiwei Zhang, Yuhan Zhang, Qinghai Meng, Yu Li, Huimin Bian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Chinese Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13020-020-00345-7 |
Similar Items
-
Synthesis, Biological Evaluation, and Pharmacokinetic Study of Novel Liguzinediol Prodrugs
by: Long Chen, et al.
Published: (2013-04-01) -
Synthesis and Biological Evaluation of Liguzinediol Mono- and Dual Ester Prodrugs as Promising Inotropic Agents
by: Jing Zhang, et al.
Published: (2014-11-01) -
The Role of the TGF-β Superfamily in Myocardial Infarction
by: Anis Hanna, et al.
Published: (2019-09-01) -
Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7
by: Jinxia Yuan, et al.
Published: (2017-08-01) -
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
by: Elias Daud, et al.
Published: (2021-07-01)